RFI: Anti-retroviral drugs for HIV/AIDS
---------------------------------------
Hello all!
I'm based in Zimbabwe, a country with one of the highest AIDS preva-
lence and incidence rates. Currently the anti-retroviral drugs for
HIV/AIDS are only available to a tiny affluent minority. I'm carrying
out a small research on the lists of ARVs, availability, cost, reim-
bursement (subsidy) policies as well as the sustainability of such a
policy change in Zimbabwe. I'm not a doctor, pharmacist but a social
activist with some health economics skills. If this research is
successful, the results would undoubtedly be very useful in other
Southern African Development Community (SADC) countries and other
parts of the world. The following are the list of drugs, which I un-
derstand are generally used.
Zidovudine (AZT)
Didanosine (ddI)
Zalcitabine (ddC)
Stavudine (d4T)
Abacavir (ABC)
Lamivudine (3TC)
Neverapine (NVP)
Delavirdine (DLV)
Efaviranez (EFV)
Saquinavir (SQV)
Ritonavir (RTV)
Indinavir (IDV)
Nelfinavir (NFV)
Could AFRO-NETS subscribers please assist with the policies and prac-
tices in their respective countries. Any suggestions on how these
drugs can be further made more affordable for the poorer sections of
our populations beyond the rhetoric of lower prices by the manufac-
turers for Sub-Saharan Africa residents?
Sincerely,
Tonderai Katsumbe
Harare, Zimbabwe
mailto:Ka_nyama@yahoo.com
--
Send mail for the `AFRO-NETS' conference to `afro-nets@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-afro-nets@usa.healthnet.org'.